Survey of the current management of secondary hyperparathyroidism (SHPT) in patients with end-stage renal disease undergoing dialysis in the UK NHS

Not Applicable

Completed

• Conditions: Secondary hyperparathyroidism; Nutritional, Metabolic, Endocrine; Secondary hyperparathyroidism, not elsewhere classified

• Registration Number: ISRCTN75383472
• Lead Sponsor: Amgen Limited (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2011-11-22
• Study Start: 2013-12-11
• Last Update Posted: 19 April 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 3000

Inclusion Criteria

1. Patients undergoing haemodialysis or peritoneal dialysis with a PTH greater than 15pMol for at least one reading in the 12 months prior to the data collection period.
2. Patients with a PTH 15pMol or less who have been prescribed a phosphate binder within the 12 months prior to the data collection period.

Exclusion Criteria

Patients undergoing dialysis for less than 90 days prior to the data collection period.

Study & Design

• Study Type: Observational
• Study Design: Not specified